The association between physical activity and cognition in men with and without HIV infection.

Abstract:

OBJECTIVES:HIV-associated neurocognitive disorders are highly prevalent, and physical activity (PA) is a modifiable behaviour that may affect neurocognitive function. Our objective was to determine the association between PA and neurocognitive function and the effect of HIV on this association. METHODS:PA was assessed in the Multicenter AIDS Cohort Study with the International Physical Activity Questionnaire. A neuropsychological test battery assessed global impairment and domain-specific impairment (executive function, speed of processing, working memory, learning, memory, and motor function) every 2 years. Semiannually, the Symbol Digit Modalities Test and Trail Making Test Parts A and B were performed. Adjusted logistic regression models were used to assess the PA-neurocognitive function association. Using longitudinal data, we also assessed the PA category-decline of neurocognitive function association with multivariate simple regression. RESULTS:Of 601 men, 44% were HIV-infected. Low, moderate, and high PA was reported in 27%, 25%, and 48% of the HIV-infected men vs. 19%, 32% and 49% of the HIV-uninfected men, respectively. High PA was associated with lower odds of impairment of learning, memory, and motor function [odds ratio (OR) ranging from 0.52 to 0.57; P < 0.05 for all]. The high PA-global impairment association OR was 0.63 [95% confidence interval (CI) 0.39, 1.02]. Among HIV-infected men only, across multiple domains, the high PA-impairment association was even more pronounced (OR from 0.27 to 0.49). Baseline high/moderate PA was not associated with decline of any domain score over time. HIV infection was marginally associated with a higher speed of decline in motor function. CONCLUSIONS:A protective effect of high PA on impairment in neurocognitive domains was observed cross-sectionally. Longitudinal PA measurements are needed to elucidate the PA-neurocognitive function relationship over time.

journal_name

HIV Med

journal_title

HIV medicine

authors

Monroe AK,Zhang L,Jacobson LP,Plankey MW,Brown TT,Miller EN,Martin E,Becker JT,Levine AJ,Ragin A,Sacktor NC

doi

10.1111/hiv.12490

subject

Has Abstract

pub_date

2017-09-01 00:00:00

pages

555-563

issue

8

eissn

1464-2662

issn

1468-1293

journal_volume

18

pub_type

杂志文章,多中心研究
  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract:OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12831

    authors: Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期:2020-07-01 00:00:00

  • Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort.

    abstract:BACKGROUND:GB virus type C (GBV-C) viraemia is associated with a beneficial outcome in HIV-infected individuals in several though not all studies. GBV-C viraemia was examined in a matched case-control study of 133 HIV-infected pregnant women who transmitted HIV to their infants ('cases') and 266 non-transmitting contro...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2007.00510.x

    authors: Handelsman E,Cheng I,Thompson B,Hershow R,Mofenson LM,Hollinger FB,Chen KT,Burchett SK,Klinzman D,Stapleton JT,Women and Infants Transmission Study Group (WITS).

    更新日期:2007-11-01 00:00:00

  • Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.

    abstract:OBJECTIVES:Three-drug nonoccupational post-exposure prophylaxis (NPEP) typically includes co-formulated emtricitabine-tenofovir (FTC-TDF) and a protease inhibitor. However, protease inhibitors can cause significant toxicities, can interact with prescribed and illicit drugs, and work late in the viral cycle. Agents that...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/hiv.12075

    authors: McAllister J,Read P,McNulty A,Tong WW,Ingersoll A,Carr A

    更新日期:2014-01-01 00:00:00

  • HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care?

    abstract:OBJECTIVES:In the UK, free HIV care is provided through dedicated HIV clinics. Using the national cohort of men who have sex with men (MSM) with diagnosed HIV infection and estimates of the number of undiagnosed men, we assessed whether high retention in HIV care and treatment coverage is sufficient to reduce HIV trans...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12066

    authors: Brown AE,Gill ON,Delpech VC

    更新日期:2013-10-01 00:00:00

  • Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy.

    abstract:OBJECTIVE:The aim of the study was to compare the incidence of anaemia in patients treated with zidovudine (ZDV) with that in patients treated with highly active antiretroviral therapy (HAART) not including ZDV. METHODS:Using HIV Insight, a database of abstracted US HIV care centre medical charts, ZDV-naïve patients s...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00500.x

    authors: Curkendall SM,Richardson JT,Emons MF,Fisher AE,Everhard F

    更新日期:2007-11-01 00:00:00

  • Universal test and treat in relation to HIV disease progression: results from a stepped-wedge trial in Eswatini.

    abstract:OBJECTIVES:Universal test and treat (UTT) is recommended for people living with HIV (PLHIV) to reduce morbidity/mortality and minimize transmission. However, concerns exist that this strategy may lead to more crowded hospitals, longer wait times and poorer service, adversely impacting health outcomes for clients with s...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12941

    authors: Boeke CE,Khan S,Walsh F,Hettema A,Lejeune C,Spiegelman D,Okello V,Harwell J,Mazibuko S,Bärnighausen T

    更新日期:2021-01-01 00:00:00

  • HIV testing strategies employed in health care settings in the European Union/European Economic Area (EU/EEA): evidence from a systematic review.

    abstract:OBJECTIVES:Despite the availability of HIV testing guidelines to facilitate prompt diagnosis, late HIV diagnosis remains high across Europe. The study synthesizes recent evidence on HIV testing strategies adopted in health care settings in the European Union/European Economic Area (EU/EEA). METHODS:Preferred Reporting...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12809

    authors: Desai S,Tavoschi L,Sullivan AK,Combs L,Raben D,Delpech V,Jakobsen SF,Amato-Gauci AJ,Croxford S

    更新日期:2020-03-01 00:00:00

  • Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy.

    abstract:BACKGROUND:Mucocutaneous manifestations such as oral candidiasis (OC) and seborrheic dermatitis (SD) are very common HIV-related opportunistic events and are usually initial markers of immunodeficiency. AIM:The purpose of this study was to evaluate the efficacy of highly active antiretroviral therapy (HAART) in the re...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1468-1293.2004.00185.x

    authors: Dunic I,Vesic S,Jevtovic DJ

    更新日期:2004-01-01 00:00:00

  • Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).

    abstract:OBJECTIVES:Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV-1-infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs. nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00917.x

    authors: Podzamczer D,Andrade-Villanueva J,Clotet B,Taylor S,Rockstroh JK,Reiss P,Domingo P,Gellermann HJ,de Rossi L,Cairns V,Soriano V

    更新日期:2011-07-01 00:00:00

  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract::Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1046/j.1468-1293.2000.00027.x

    authors: Hermans P

    更新日期:2000-07-01 00:00:00

  • The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

    abstract::Tenofovir (TDF) co-administered with didanosine (ddI) 400 mg increases ddI plasma concentrations by up to 60%, raising concerns over toxicity. To limit this interaction, the dosage of ddI may be reduced to 250 mg once daily when co-prescribed with TDF. In this clinical cohort, highly active antiretroviral therapy regi...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00279.x

    authors: Tung MY,Mandalia S,Bower M,Gazzard B,Nelson M

    更新日期:2005-05-01 00:00:00

  • Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

    abstract:BACKGROUND:The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy wit...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2009.00752.x

    authors: Ghosn J,Flandre P,Cohen-Codar I,Girard PM,Chaix ML,Raffi F,Dellamonica P,Ngovan P,Norton M,Delfraissy JF,MONARK Study Group.

    更新日期:2010-02-01 00:00:00

  • Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada.

    abstract:OBJECTIVES:Outbreaks of shigellosis have been documented in men who have sex with men (MSM), associated with interpersonal transmission and underlying HIV infection. We observed a rise in Shigella flexneri isolates identified in a downtown tertiary-care hospital laboratory located within the city centre community healt...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12191

    authors: Wilmer A,Romney MG,Gustafson R,Sandhu J,Chu T,Ng C,Hoang L,Champagne S,Hull MW

    更新日期:2015-03-01 00:00:00

  • Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.

    abstract:OBJECTIVES:Direct-acting antiviral agents (DAAs) have become the standard of care for the treatment of chronic hepatitis C virus (HCV) infection. We aimed to assess treatment uptake and efficacy in routine clinical settings among HIV/HCV coinfected patients after the introduction of the first generation DAAs. METHODS:...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12269

    authors: Schaerer V,Haubitz S,Kovari H,Ledergerber B,Ambrosioni J,Cavassini M,Stoeckle M,Schmid P,Decosterd L,Aouri M,Böni J,Günthard HF,Furrer H,Metzner KJ,Fehr J,Rauch A,Swiss HIV Cohort Study.

    更新日期:2015-11-01 00:00:00

  • Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study.

    abstract:OBJECTIVES:To assess the effect of chronic hepatitis B on survival and clinical complexity among people living with HIV following antiretroviral therapy (ART) initiation. METHODS:We evaluated mortality and single-drug substitutions up to 3 years from ART initiation (median follow-up 2.75 years; interquartile range 2-3...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12367

    authors: Velen K,Charalambous S,Innes C,Churchyard GJ,Hoffmann CJ

    更新日期:2016-10-01 00:00:00

  • Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

    abstract:OBJECTIVES:Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are l...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12488

    authors: Gallien S,Journot V,Loriot MA,Sauvageon H,Morlat P,Reynes J,Reliquet V,Chêne G,Molina JM,ANRS 099 ALIZE trial study group.

    更新日期:2017-09-01 00:00:00

  • Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.

    abstract:OBJECTIVE:To compare virological and immunological responses to nevirapine (NVP)-based and efavirenz (EFV)-based highly active antiretroviral therapy (HAART) regimens in antiretroviral-naïve patients with advanced HIV infection. METHODS:A retrospective observational cohort study was conducted on antiretroviral-naïve H...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00195.x

    authors: Manosuthi W,Sungkanuparph S,Vibhagool A,Rattanasiri S,Thakkinstian A

    更新日期:2004-03-01 00:00:00

  • Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B*5701 in HIV-1-infected UK subjects.

    abstract:OBJECTIVES:Human leukocyte antigen (HLA)-B(*)5701 is strongly associated with developing a hypersensitivity reaction to abacavir (ABC) in White and Hispanic subjects. Across the UK, limited data exist on HLA-B(*)5701 prevalence in HIV-1-infected subjects. We determined HLA-B(*)5701 prevalence in the general HIV-1-infec...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2009.00762.x

    authors: Orkin C,Sadiq ST,Rice L,Jackson F,UK EPI team.

    更新日期:2010-03-01 00:00:00

  • Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe.

    abstract:OBJECTIVES:The aim of the study was to investigate the prevalence of and risk factors for hepatitis C or B virus (HCV or HBV) coinfection among HIV-infected pregnant women, and to investigate their immunological and virological characteristics and antiretroviral therapy use. METHODS:Information on HBV surface antigen ...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00599.x

    authors: Landes M,Newell ML,Barlow P,Fiore S,Malyuta R,Martinelli P,Posokhova S,Savasi V,Semenenko I,Stelmah A,Tibaldi C,Thorne C

    更新日期:2008-08-01 00:00:00

  • End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years.

    abstract:OBJECTIVES:Renal disease is a common and serious complication in HIV-infected patients. METHODS:A retrospective cohort analysis for the period 1989-2010 was carried out to determine the prevalence, incidence and risk factors for end-stage renal disease (ESRD). ESRD was defined as initiation of renal replacement therap...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.01045.x

    authors: Bickel M,Marben W,Betz C,Khaykin P,Stephan C,Gute P,Haberl A,Knecht G,Wolf T,Brodt HR,Geiger H,Herrmann E,Jung O

    更新日期:2013-03-01 00:00:00

  • Euthanasia: from the perspective of HIV infected persons in Europe.

    abstract:BACKGROUND:In the debate about legalization of euthanasia very little attention has so far been given to the opinion of the patient. OBJECTIVE:To assess the opinion of persons with HIV infection in Europe. METHODS:A cross-sectional survey of persons with HIV infection attending HIV/AIDS treatment centres or HIV suppo...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00053.x

    authors: Andraghetti R,Foran S,Colebunders R,Tomlinson D,Vyras P,Borleffs CJ,Fleerackers Y,Schrooten W,Borchert M

    更新日期:2001-01-01 00:00:00

  • Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

    abstract:OBJECTIVE:The aim of the study was to evaluate the predictive value of clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), for the development of lactic acidosis (LA) and symptomatic hyperlactataemia (SHL). METHODS:In a substu...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00934.x

    authors: Feeney ER,Chazallon C,O'Brien N,Meiffrédy V,Goodall RL,Aboulker JP,Cooper DA,Yeni P,Mallon PW,INITIO Trial International Co-ordinating Committee.

    更新日期:2011-11-01 00:00:00

  • Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.

    abstract:OBJECTIVES:TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant, protease inhibitor-naïve, HIV-1-infected patients. ...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2008.00644.x

    authors: Ruxrungtham K,Pedro RJ,Latiff GH,Conradie F,Domingo P,Lupo S,Pumpradit W,Vingerhoets JH,Peeters M,Peeters I,Kakuda TN,De Smedt G,Woodfall B,TMC125-C227 study group.

    更新日期:2008-11-01 00:00:00

  • Hepatitis C in men who have sex with men in London--a community survey.

    abstract:OBJECTIVES:For the last 10 years there has been an epidemic of hepatitis C virus (HCV) infection in men who have sex with men (MSM) in Europe, North America and Australia. The majority of those infected are also HIV-positive and it is unclear to what extent HIV-negative MSM are also at increased risk of infection with ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12050

    authors: Price H,Gilson R,Mercey D,Copas A,Parry J,Nardone A,Johnson A,Hart G

    更新日期:2013-10-01 00:00:00

  • Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months.

    abstract:OBJECTIVE:To quantify HIV-RNA in plasma, in lymphoid tissue and proviral DNA in peripheral blood mononuclear cells and to relate these to immunological markers among patients with plasma viral load counts of

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2003.00119.x

    authors: Katzenstein TL,Ullum H,Røge BT,Wandall J,Dickmeiss E,Barrington T,Skinhøj P,Gerstoft J

    更新日期:2003-01-01 00:00:00

  • Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.

    abstract:OBJECTIVES:We evaluated the emergence of drug resistance in patients failing first-line regimens containing one nonnucleoside reverse transcriptase inhibitor (NNRTI) administered with zidovudine (ZDV) + lamivudine (the ZDV group) or non-thymidine analogues (non-TAs) (tenofovir or abacavir, + lamivudine or emtricitabine...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12044

    authors: Santoro MM,Sabin C,Forbici F,Bansi L,Dunn D,Fearnhill E,Boumis E,Nicastri E,Antinori A,Palamara G,Callegaro A,Francisci D,Zoncada A,Maggiolo F,Zazzi M,Perno CF,Ceccherini-Silberstein F,Mussini C

    更新日期:2013-10-01 00:00:00

  • Human leucocyte antigen (HLA)-DQB1*03:02 and HLA-A*02:01 have opposite patterns in their effects on susceptibility to HIV infection.

    abstract:OBJECTIVES:The objective of this study was to seek correlates of immune protection in HIV infection. We sought to elucidate the association between the presence of human leucocyte antigen (HLA) alleles, as well as killer immunoglobulin receptor (KIR) genotypes, and the susceptibility to HIV infection in a Spanish cohor...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12494

    authors: Rallón N,Restrepo C,Vicario JL,Del Romero J,Rodríguez C,García-Samaniego J,García M,Cabello A,Górgolas M,Benito JM

    更新日期:2017-09-01 00:00:00

  • HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.

    abstract:OBJECTIVE:To establish the prevalence, severity and factors associated with the HIV lipodystrophy syndrome. METHODS:Cross-sectional study of lipodystrophy conducted in high HIV caseload primary care sites and HIV outpatient clinics. A subset of patients was examined using dual energy X-ray absorptiometry (DEXA) and si...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1046/j.1468-1293.2003.00159.x

    authors: Miller J,Carr A,Emery S,Law M,Mallal S,Baker D,Smith D,Kaldor J,Cooper DA

    更新日期:2003-07-01 00:00:00

  • Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

    abstract:OBJECTIVES:Pregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/rit...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12164

    authors: Else LJ,Jackson V,Brennan M,Back DJ,Khoo SH,Coulter-Smith S,Lambert JS

    更新日期:2014-11-01 00:00:00

  • Mitochondrial DNA depletion in liver tissue of patients infected with hepatitis C virus: contributing effect of HIV infection?

    abstract:OBJECTIVES:It has been suggested that chronic hepatitis C virus (HCV) infection depletes mitochondrial DNA (mtDNA) in the liver. Because decreased mtDNA levels were also found in humans infected with HIV, we investigated whether HIV may have aggravated hepatic mtDNA depletion in individuals with HCV infection. METHODS...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2005.00276.x

    authors: Bäuerle J,Laguno M,Mauss S,Mallolas J,Murillas J,Miquel R,Schmutz G,Setzer B,Gatell JM,Walker UA

    更新日期:2005-03-01 00:00:00